ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 833

Chronic Cutaneous Lupus Erythematosus Patients Have a Breakdown in Autoreactive VH4.34 Antibody Tolerance While Maintaining Tolerance to dsDNA and Chromatin

Scott Jenks1, Regina Bugrovsky1, Xiaoqian Wang1,2, Aisha Hill3, Chungwen Wei4, S. Sam Lim5, Ignacio Sanz6 and Cristina Drenkard5, 1Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, 2Division of Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine, Atlanta, GA, 3Medicine, Emory University School of Medicine, atlanta, GA, 4Medicine, Emory University School of Medicine, Atlanta, GA, 5Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, 6Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: anti-dsDNA, autoantibodies and cutaneous lupus erythematosus, B cell tolerance, SLE

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: While the contribution of humoral immunity to SLE is well established, the role it plays in chronic cutaneous lupus erythematosus (CCLE) is less clear. One characteristic of SLE is a breakdown of tolerance in autoreactive VH4.34 antibodies that are recognized by the rat anti-human idiotypic antibody 9G4 (9G4+). 9G4+ antibodies have germ line encoded autoreactive specificity for glycolipids found on red blood cells and B cells. Despite a high frequency of naive 9G4+ B cells, healthy control donors (HC) have low amounts of serum 9G4+ IgG. In contrast, many SLE patients have high levels of serum 9G4+ IgG that is associated with higher disease activity and highly correlated with anti-dsDNA and a substantial proportion of anti-dsDNA antibodies are 9G4+. The purpose of this study was to compare 9G4+ IgG and associated SLE auto-antibodies between CCLE patients and SLE patients.

Methods: We analyzed samples from 36 HC and 52 patients with primary CCLE, 44 SLE with CCLE, and 303 SLE without CCLE. Cases with a validated diagnosis of either discoid, panniculitis, tumidus or chilblain lupus were included as CCLE. The ACR criteria and attending rheumatologist/dermatologist judgement were used to classify CCLE cases as primary or associated with SLE. We used ELISA to measure 9G4 with the rat monoclonal 9G4, and goat anti-human IgG. Anti-dsDNA and anti-chromatin IgG were measured using commercial ELISA kits. B cell binding 9G4+ was evaluated ex-vivo by flow cytometry.

Results:

41% of SLE patients were positive for 9G4 IgG and had significantly higher serum concentration than HC (p<0.001) Surprisingly, CCLE patients also had high levels of 9G4+ IgG, 38% were positive and serum concentrations were significantly higher than HC (p<0.001) and did not statistically differ from SLE patients. In contrast, while many SLE patients had anti-dsDNA (48%) and anti-chromatin (52%), few CCLE patients were positive for these specificities (12% and 21%) and the concentration was significantly lower for both (p<0.001). Consequently, 9G4+ IgG concentration was highly correlated with both anti-dsDNA (p<0.001, r=0.48) and anti-chromatin (p<0.001, r=0.45) concentration in SLE patients but not in CCLE patients. CCLE patients, however, did have auto-reactive 9G4+, as B cell binding antibodies were similar between SLE and CCLE patients.

Conclusion: Our study confirms the correlation between 9G4+ IgG and anti-dsDNA in SLE and extends this to anti-chromatin. Surprisingly, CCLE patients had high levels of 9G4+ IgG but not anti-dsDNA. This suggests a two-step model of 9G4 tolerance in SLE, the breakdown of general tolerance of germline encoded autoreactive VH4.34 antibodies and a subsequent development of 9G4+ specific for dsDNA. CCLE patients clearly have a defect in the first step and the mechanism of this defect is potentially shared between CCLE and SLE. However, the second step is not shared, as CCLE patients with 9G4+ IgG do not have high levels of anti-dsDNA. Regulation of this step may help determine if otherwise immunologically similar patients may develop SLE or CCLE. Because the specificity of 9G4+ in CCLE is unknown, it remains to be determined whether these antibodies contribute directly to CCLE disease


Disclosure: S. Jenks, None; R. Bugrovsky, None; X. Wang, None; A. Hill, None; C. Wei, None; S. S. Lim, None; I. Sanz, None; C. Drenkard, None.

To cite this abstract in AMA style:

Jenks S, Bugrovsky R, Wang X, Hill A, Wei C, Lim SS, Sanz I, Drenkard C. Chronic Cutaneous Lupus Erythematosus Patients Have a Breakdown in Autoreactive VH4.34 Antibody Tolerance While Maintaining Tolerance to dsDNA and Chromatin [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/chronic-cutaneous-lupus-erythematosus-patients-have-a-breakdown-in-autoreactive-vh4-34-antibody-tolerance-while-maintaining-tolerance-to-dsdna-and-chromatin/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2017

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chronic-cutaneous-lupus-erythematosus-patients-have-a-breakdown-in-autoreactive-vh4-34-antibody-tolerance-while-maintaining-tolerance-to-dsdna-and-chromatin/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology